A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors.

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in ...

Learn how ATTR-CM is diagnosed, common warning signs, and why early detection is important to healthy outcomes.

Social Security makes it easier for people with severe medical conditions to access disability benefits by adding 13 diseases to the list.

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.

HHS is slashing hundreds of millions in funding for mRNA vaccines and infectious disease treatments, but leaving the door ...

– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL ...

Shares of Prothena climbed after Novo Nordisk said during its second-quarter earnings call that it expects to advance a treatment for amyloidosis it bought from Prothena in 2021. The Dublin company's ...

A recent study led by a team of researchers at The Johns Hopkins University School of Medicine examining aging mice has ...

An extraordinary connection has formed between a mother who lost her daughter and a woman whose life was saved by that ...